{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:14:46Z","timestamp":1780614886473,"version":"3.54.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Skin cutaneous melanoma (SKCM) is a highly aggressive malignancy originating from melanocytes, with a continuously rising global incidence. Developing strategies for early prevention and precise treatment remains a major challenge in oncology. Notably, advances in immunotherapy have brought new hope to SKCM patients. Increasing evidence suggests that various forms of regulated cell death, particularly cuproptosis and ferroptosis, can modulate the tumor microenvironment (TME) by inducing the death of both tumor and immune cells, thereby influencing the efficacy of immunotherapy. Consequently, there is a critical need to establish methods for early diagnosis and to develop reliable prognostic models prognostic models based on immune-related biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated RNA sequencing data and corresponding clinical information from SKCM patients obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Using single-cell transcriptomic data from the GSE72056 dataset, we analyzed the expression patterns of cuproptosis-ferroptosis-related genes (CFRGs) in SKCM and their enrichment in immune cell subsets. Key CFRG features were screened using machine learning algorithms to construct a prognostic risk-scoring model, which demonstrated robust predictive performance across multiple independent cohorts. Furthermore, we explored the associations between core CFRGs and patient survival outcomes, immunotherapy response, and drug sensitivity in SKCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 10 key genes that were significantly associated with SKCM survival and successfully constructed a machine learning-based prognostic prediction model. This model showed strong predictive performance and demonstrated superior accuracy compared with existing prognostic models, as supported by cross-cohort and cross-cancer validation. Four key genes (IFNG, PTPN6, SLC38A1, and SOCS1) were further identified through association analyses with clinical phenotypes and showed significant correlations with clinical characteristics. Distinct immune cell infiltration patterns were observed between high- and low-risk groups stratified by these genes, indicating marked heterogeneity within the TME. This heterogeneity may directly influence patient responses to immunotherapy. Additionally, molecular docking analyses identified several potential therapeutic compounds, among which selumetinib demonstrated strong binding affinity to the target proteins IFNG, PTPN6, and SOCS1, suggesting a potential therapeutic strategy for advanced SKCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IFNG, PTPN6, SLC38A1, and SOCS1 may serve as potential biomarkers of poor prognosis in SKCM patients. These genes demonstrate predictive value for immunotherapy response and drug sensitivity, particularly indicating susceptibility to selumetinib treatment, and therefore show substantial potential for clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1742614","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:21Z","timestamp":1768372881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating cuproptosis- and ferroptosis-related gene signatures to predict prognosis, immunotherapy response, and drug sensitivity in patients with skin cutaneous melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Hua","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Oncology Department, Xinqiao Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaofeng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Southwest Hospital, Third Military Medical University (Army Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387316","article-title":"Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM","volume":"15","author":"Rong","year":"2024","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919145","article-title":"The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","article-title":"Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research","volume":"15","author":"Tong","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12935-024-03220-9","article-title":"Melanoma biology and treatment: a review of novel regulated cell death-based approaches","volume":"24","author":"Hsieh","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110173","article-title":"Essential metals in health and disease","volume":"367","author":"Jomova","year":"2022","journal-title":"Chem Biol Interact"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13276","article-title":"Copper homeostasis and cuproptosis in cancer immunity and therapy","volume":"321","author":"Liu","year":"2024","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-017-0053-8","article-title":"miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma","volume":"25","author":"Luo","year":"2018","journal-title":"Cell Death Differ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1000993","article-title":"A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: Current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102556","article-title":"Autoimmune-related adverse events induced by immune checkpoint inhibitors","volume":"94","author":"Sun","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128390","article-title":"Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy","volume":"14","author":"Hong","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2302640","DOI":"10.1002\/advs.202302640","article-title":"Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients","volume":"10","author":"Zou","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2023.11.004","article-title":"Prognostic and predictive biomarkers in melanoma","volume":"56","author":"Maher","year":"2024","journal-title":"Pathology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00910-y","article-title":"Prognostic biomarkers in evolving melanoma immunotherapy","volume":"26","author":"Reschke","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/156800908784293659","article-title":"The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications","volume":"8","author":"Carnero","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"B26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-021-01064-4","article-title":"Cytokines in the treatment of melanoma","volume":"23","author":"Bentebibel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.jid.2019.02.016","article-title":"Regulatory B1a cells suppress melanoma tumor immunity via IL-10 production and inhibiting T helper type 1 cytokine production in tumor-infiltrating CD8(+) T cells","volume":"139","author":"Kobayashi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00948-2","article-title":"Promising blood-based biomarkers for melanoma: recent progress of liquid biopsy and its future perspectives","volume":"23","author":"Kanemaru","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00119","article-title":"Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma","volume":"5","author":"Hsueh","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.952290","article-title":"Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.972899","article-title":"Construction of five cuproptosis-related lncRNA signature for predicting prognosis and immune activity in skin cutaneous melanoma","volume":"13","author":"Yang","year":"2022","journal-title":"Front Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12672-025-01992-8","article-title":"CDKN2A, a key gene in copper-induced cell death model, influencing melanoma invasion and apoptosis","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03504-5","article-title":"Role of single-cell ferroptosis regulation in intercellular communication and skin cutaneous melanoma progression and immunotherapy","volume":"72","author":"Song","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.985051","article-title":"Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e70394","DOI":"10.1096\/fj.202402285R","article-title":"PTPN9 promotes melanoma progression by regulating the ferroptosis pathway","volume":"39","author":"Wang","year":"2025","journal-title":"FASEB J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1295687","article-title":"Multiple cell-death patterns predict the prognosis and drug sensitivity of melanoma patients","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev Sep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S441135","article-title":"TME-related biomimetic strategies against cancer","volume":"19","author":"Peng","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02561-x","article-title":"Interferon-gamma signaling promotes melanoma progression and metastasis","volume":"42","author":"Zhou","year":"2023","journal-title":"Oncogene"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0087","article-title":"The interferon-gamma paradox in cancer","volume":"39","author":"Zaidi","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216466","article-title":"Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses","volume":"581","author":"Hu","year":"2024","journal-title":"Cancer Lett"},{"key":"B49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2018.01.014","article-title":"IFN-\u03b3 and tumor gangliosides: Implications for the tumor microenvironment","volume":"325","author":"Dillinger","year":"2018","journal-title":"Cell Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s12672-025-03038-5","article-title":"Exploring PTPN6 as a dual oncogenic and immunological marker in melanoma","volume":"16","author":"Bian","year":"2025","journal-title":"Discov Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12935-024-03625-6","article-title":"Prognostic value and immune infiltration of a tumor microenvironment-related PTPN6 in metastatic melanoma","volume":"24","author":"Sun","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576310","article-title":"Shp1 loss enhances macrophage effector function and promotes anti-tumor immunity","volume":"11","author":"Myers","year":"2020","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2427254122","DOI":"10.1073\/pnas.2427254122","article-title":"T lymphocyte-specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4(+) T cells and impairs antitumor response","volume":"122","author":"Foster","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-19-0690","article-title":"Inhibition of SHP-1 expands the repertoire of antitumor T cells available to respond to immune checkpoint blockade","volume":"8","author":"Snook","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"11025","DOI":"10.1038\/s41598-025-96302-1","article-title":"Multi-omic analyses reveal PTPN6\u2019s impact on tumor immunity across various cancers","volume":"15","author":"Zhong","year":"2025","journal-title":"Sci Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3390\/cancers14092151","article-title":"Role of amino acid transporter SNAT1\/SLC38A1 in human melanoma","volume":"14","author":"B\u00f6hme-Sch\u00e4fer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1145-8","article-title":"Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells","volume":"70","author":"Parrillas","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/srep40585","article-title":"SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression","volume":"7","author":"Berzaghi","year":"2017","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-1429","article-title":"Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis","volume":"68","author":"Huang","year":"2008","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01098.x","article-title":"Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation","volume":"100","author":"Hashimoto","year":"2009","journal-title":"Cancer Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1172\/jci26169","article-title":"SOCS1 restricts dendritic cells\u2019 ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling","volume":"116","author":"Evel-Kabler","year":"2006","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01007-y","article-title":"TRIM22 promotes the proliferation of glioblastoma cells by activating MAPK signaling and accelerating the degradation of Raf-1","volume":"55","author":"Fei","year":"2023","journal-title":"Exp Mol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00783-z","article-title":"Selumetinib: a selective MEK1 inhibitor for solid tumor treatment","volume":"23","author":"Hedayat","year":"2023","journal-title":"Clin Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114009","article-title":"A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma","volume":"202","author":"Sacco","year":"2024","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S51596","article-title":"Profile of selumetinib and its potential in the treatment of melanoma","volume":"7","author":"Kim","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.665871","article-title":"Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma","volume":"21","author":"Patel","year":"2012","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1742614\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:24Z","timestamp":1768372884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1742614\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2025.1742614"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1742614","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1742614"}}